Markus Dold

Markus Dold

Auto-generated profile, based on publicly available information

Markus Dold

Department of Psychiatry and Psychotherapy, Medical University of VIenna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
SLStefan Leucht
Stefan Leucht
SHSandra Hierl
Sandra Hierl
WKWerner Kissling
Werner Kissling
MDMarkus Dold
Markus Dold
JDJohn M. Davis
John M. Davis
Background: The efficacy of psychopharmacological treatments has been called into question. Psychiatrists are unfamiliar with the effectiveness of common medical drugs.Aims: To put the efficacy of psychiatric drugs into the perspective of that of major medical drugs.Method: We searched Medline and the Cochrane Library for systematic reviews on the efficacy of drugs compared with placebo for common medical and psychiatric disorders, and systematically presented the effect sizes for primary efficacy outcomes.Results: We included 94 meta-analyses (48 drugs in 20 medical diseases, 16 drugs in 8 psychiatric disorders). There were some general medical drugs with clearly higher effect sizes than the psychotropic agents, but the psychiatric drugs were not generally less efficacious than other drugs.Conclusions: Any comparison of different outcomes in different diseases can only serve the purpose of a qualitative perspective. The increment of improvement by drug over placebo must be viewed in the context of the disease's seriousness, suffering induced, natural course, duration, outcomes, adverse events and societal values.

1 June 2014 in JAMA Psychiatry
Verified
Journal Article
Closed access
PDF file
MHMaximilian Huhn
Maximilian Huhn
MTMagdolna Tardy
Magdolna Tardy
LSLoukia Maria Spineli
Loukia Maria Spineli
WKWerner Kissling
Werner Kissling
HFHans Förstl
Hans Förstl
SLStefan Leucht
Stefan Leucht
Importance There is debate about the effectiveness of psychiatric treatments and whether pharmacotherapy or psychotherapy should be primarily used. Objectives To perform a systematic overview on the efficacy of pharmacotherapies and psychotherapies for major psychiatric disorders and to compare the quality of pharmacotherapy and psychotherapy trials. Evidence Review We searched MEDLINE, EMBASE, PsycINFO, and the Cochrane Library (April 2012, with no time or language limit) for systematic reviews on pharmacotherapy or psychotherapy vs placebo, pharmacotherapy vs psychotherapy, and their combination vs either modality alone. Two reviewers independently selected the meta-analyses and extracted efficacy effect sizes. We assessed the quality of the individual trials included in the pharmacotherapy and psychotherapy meta-analyses with the Cochrane risk of bias tool. Findings The search yielded 45 233 results. We included 61 meta-analyses on 21 psychiatric disorders, which contained 852 individual trials and 137 126 participants. The mean effect size of the meta-analyses was medium (mean, 0.50; 95% CI, 0.41-0.59). Effect sizes of psychotherapies vs placebo tended to be higher than those of medication, but direct comparisons, albeit usually based on few trials, did not reveal consistent differences. Individual pharmacotherapy trials were more likely to have large sample sizes, blinding, control groups, and intention-to-treat analyses. In contrast, psychotherapy trials had lower dropout rates and provided follow-up data. In psychotherapy studies, wait-list designs showed larger effects than did comparisons with placebo. Conclusions and Relevance Many pharmacotherapies and psychotherapies are effective, but there is a lot of room for improvement. Because of the multiple differences in the methods used in pharmacotherapy and psychotherapy trials, indirect comparisons of their effect sizes compared with placebo or no treatment are problematic. Well-designed direct comparisons, which are scarce, need public funding. Because patients often benefit from both forms of therapy, research should also focus on how both modalities can be best combined to maximize synergy rather than debate the use of one treatment over the other.

1 March 2016 in JAMA Psychiatry
Verified
Journal Article
Closed access
PDF file
MSMyrto T. Samara
Myrto T. Samara
MDMarkus Dold
Markus Dold
MGMyrsini Gianatsi
Myrsini Gianatsi
ANAdriani Nikolakopoulou
Adriani Nikolakopoulou
BHBartosz Helfer
Bartosz Helfer
SLStefan Leucht
Stefan Leucht
Research from JAMA Psychiatry — Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia — A Network Meta-analysis

3 July 2019 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
Lucie BartovaLucie Bartova
Lucie Bartova
MDMarkus Dold
Markus Dold
Alexander KautzkyAlexander Kautzky
Alexander Kautzky
CFChiara Fabbri
Chiara Fabbri
MSMarie Spies
Marie Spies
SKSiegfried Kasper
Siegfried Kasper
Objectives: The overview outlines two decades of research from the European Group for the Study of Resistant Depression (GSRD) that fundamentally impacted evidence-based algorithms for diagnostics and psychopharmacotherapy of treatment-resistant depression (TRD). Methods: The GSRD staging model characterising response, non-response and resistance to antidepressant (AD) treatment was applied to 2762 patients in eight European countries. Results: In case of non-response, dose escalation and switching between different AD classes did not show superiority over continuation of original AD treatment. Predictors for TRD were symptom severity, duration of the current major depressive episode (MDE), suicidality, psychotic and melancholic features, comorbid anxiety and personality disorders, add-on treatment, non-response to the first AD, adverse effects, high occupational level, recurrent disease course, previous hospitalisations, positive family history of MDD, early age of onset and novel associations of single nucleoid polymorphisms (SNPs) within the PPP3CC, ST8SIA2, CHL1, GAP43 and ITGB3 genes and gene pathways associated with neuroplasticity, intracellular signalling and chromatin silencing. A prediction model reaching accuracy of above 0.7 highlighted symptom severity, suicidality, comorbid anxiety and lifetime MDEs as the most informative predictors for TRD. Applying machine-learning algorithms, a signature of three SNPs of the BDNF, PPP3CC and HTR2A genes and lacking melancholia predicted treatment response. Conclusions: The GSRD findings offer a unique and balanced perspective on TRD representing foundation for further research elaborating on specific clinical and genetic hypotheses and treatment strategies within appropriate study-designs, especially interaction-based models and randomized controlled trials.

5 October 2018 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Open access
PDF file
Alexander KautzkyAlexander Kautzky
Alexander Kautzky
MDM. Dold
M. Dold
Lucie BartovaLucie Bartova
Lucie Bartova
MSM. Spies
M. Spies
GKG. S. Kranz
G. S. Kranz
SKSiegfried Kasper
Siegfried Kasper
Objectives: Clinical variables were investigated in the ‘treatment resistant depression ( TRD )‐ III ’ sample to replicate earlier findings by the European research consortium ‘Group for the Study of Resistant Depression’ ( GSRD ) and enable cross‐sample prediction of treatment outcome in TRD . Experimental procedures: TRD was defined by a Montgomery and Åsberg Depression Rating Scale ( MADRS ) score ≥22 after at least two antidepressive trials. Response was defined by a decline in MADRS score by ≥50% and below a threshold of 22. Logistic regression was applied to replicate predictors for TRD among 16 clinical variables in 916 patients. Elastic net regression was applied for prediction of treatment outcome. Results: Symptom severity (odds ratio ( OR ) = 3.31), psychotic symptoms ( OR = 2.52), suicidal risk ( OR = 1.74), generalized anxiety disorder ( OR = 1.68), inpatient status ( OR = 1.65), higher number of antidepressants administered previously ( OR = 1.23), and lifetime depressive episodes ( OR = 1.15) as well as longer duration of the current episode ( OR = 1.022) increased the risk of TRD . Prediction of TRD reached an accuracy of 0.86 in the independent validation set, TRD ‐I. Conclusion: Symptom severity, suicidal risk, higher number of lifetime depressive episodes, and comorbid anxiety disorder were replicated as the most prominent risk factors for TRD . Significant predictors in TRD ‐ III enabled robust prediction of treatment outcome in TRD ‐I.

1 October 2019 in Psychotherapy and Psychosomatics
Verified
Journal Article
Closed access
PDF file
EWEdda Winkler-Pjrek
Edda Winkler-Pjrek
MFMichaela-Elena Friedrich
Michaela-Elena Friedrich
LCLuca Cambioli
Luca Cambioli
MDMarkus Dold
Markus Dold
FJFiona Jäger
Fiona Jäger
DWDietmar Winkler
Dietmar Winkler
Background: Bright light therapy (BLT) has been used as a treatment for seasonal affective disorder (SAD) for over 30 years. This meta-analysis was aimed to assess the efficacy of BLT in the treatment of SAD in adults. Method: We performed a systematic literature search including randomized, single- or double-blind clinical trials investigating BLT (≥1,000 lx, light box or light visor) against dim light (≤400 lx) or sham/low-density negative ion generators as placebo. Only first-period data were used from crossover trials. The primary outcome was the post-treatment depression score measured by validated scales, and the secondary outcome was the rate of response to treatment. Results: A total of 19 studies finally met our predefined inclusion criteria. BLT was superior over placebo with a standardized mean difference of –0.37 (95% CI: –0.63 to –0.12) for depression ratings (18 studies, 610 patients) and a risk ratio of 1.42 (95% CI: 1.08–1.85) for response to active treatment (16 studies, 559 patients). We found no evidence for a publication bias, but moderate heterogeneity of the studies and a moderate-to-high risk of bias. Conclusions: BLT can be regarded as an effective treatment for SAD, but the available evidence stems from methodologically heterogeneous studies with small-to-medium sample sizes, necessitating larger high-quality clinical trials.